FDA Determines Regulatory Review Period for BYSTOLIC Patent Extension

Summary

The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of BYSTOLIC, a human drug product, as required by law following a submission to the Director of Patents and Trademarks at the Department of Commerce.